文献速递糖尿病垂体与肾上腺疾病

控制不佳的2型糖尿病合并皮质醇增多症:米非司酮治疗改善血糖

Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.
PubMed 文献 · Diabetes Care · 2025-01-01

这项前瞻性、多中心、双盲研究纳入136例血糖控制不佳(HbA1c 7.5%-11.5%)且经地塞米松抑制试验证实皮质醇增多症的2型糖尿病患者,按2:1随机接受米非司酮(300-900 mg每日一次,n=91)或安慰剂(n=45)治疗24周。结果显示米非司酮组HbA1c较安慰剂组降低1.32%(95%CI -1.81至-0.83;P<0.001),并伴体重和腰围下降,但46%的米非司酮组患者中断治疗。

要点

  • 米非司酮组24周HbA1c较安慰剂组降低1.32%(95%CI -1.81至-0.83;P<0.001)。
  • 米非司酮组体重和腰围分别较安慰剂组降低5.12 kg和5.1 cm。
  • 米非司酮组46%中断治疗,安慰剂组18%;不良事件包括低钾血症、乏力、恶心等。

核心结论

  • 在血糖控制不佳的2型糖尿病合并皮质醇增多症患者中,米非司酮靶向皮质醇的药物治疗降低了HbA1c,耐受性总体可控。

研究设计与样本

  • 前瞻性、多中心、双盲研究,136例接受多种降糖药物且HbA1c 7.5%-11.5%(58-102 mmol/mol)、经地塞米松抑制试验证实皮质醇增多症的2型糖尿病患者,按2:1随机分为米非司酮组(300-900 mg每日一次;n=91)和安慰剂组(n=45),治疗24周,按肾上腺影像学异常存在与否分层。

主要发现

  • 研究队列基线平均HbA1c为8.55%(69.9 mmol/mol)。
  • 24周时,米非司酮组HbA1c较安慰剂组的最小二乘均值(LSM)差异为-1.32%(95%CI -1.81至-0.83;P<0.001)。
  • 米非司酮组体重较安慰剂组LSM差异为-5.12 kg(95%CI -8.20至-2.03),腰围LSM差异为-5.1 cm(95%CI -8.23至-1.99)。
  • 米非司酮组46%中断治疗,安慰剂组18%。
  • 米非司酮组发生率>10%的不良事件包括低钾血症、乏力、恶心、呕吐、头痛、外周水肿、腹泻和头晕,并出现血压升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In many individuals, type 2 diabetes (T2D) remains poorly controlled despite taking multiple glucose-lowering therapies. Several studies have demonstrated that endogenous hypercortisolism is prevalent among these individuals. We tested whether cortisol-directed therapy improves their glycemic control. RESEARCH DESIGN AND METHODS: In this prospective, multicenter, double-blind study, 136 individuals with T2D (hemoglobin A1c [HbA1c] 7.5%-11.5% [58-102 mmol/mol] on multiple medications) and hypercortisolism (by dexamethasone suppression test) were randomized 2:1 to the glucocorticoid receptor antagonist mifepristone (300-900 mg once daily; n = 91) or placebo (n = 45) for 24 weeks, with stratification by presence/absence of an adrenal imaging abnormality. The primary end point was the change in HbA1c. Secondary end points included changes in glucose-lowering medications, weight, and waist circumference and safety. RESULTS: Mean baseline HbA1c in the study cohort was 8.55% (69.9 mmol/mol). At 24 weeks, the least squares mean (LSM) difference from placebo in HbA1c was -1.32% (95% CI -1.81 to -0.83; P < 0.001). Participants receiving mifepristone experienced reductions in body weight and waist circumference (placebo-adjusted LSM differences of -5.12 kg [95% CI -8.20 to -2.03] and -5.1 cm [-8.23 to -1.99], respectively). Of participants on mifepristone, 46% discontinued therapy, compared with 18% on placebo. Adverse events with mifepristone (>10% of participants) included hypokalemia, fatigue, nausea, vomiting, headache, peripheral edema, diarrhea, and dizziness, consistent with mifepristone's known tolerability profile. Increases in blood pressure also occurred. CONCLUSIONS: In individuals with inadequately controlled T2D and hypercortisolism, cortisol-directed medical therapy with mifepristone reduced HbA1c, with a manageable tolerability profile.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. DeFronzo RA, Fonseca V, Aroda VR, et al. Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care. 2025. PMID: 40550011. doi:10.2337/dc25-1055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。